In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)

October 9, 2020

Plaintiff States sought damages and injunctive relief, alleging that defendants entered into an unlawful agreement attempting to delay or prevent the marketing of less expensive generic alternatives to Cardizem CD, a brand name drug used to prevent heart attacks. The Plaintiff States settled for $80 million, the bulk of which was to be used to reimburse purchasers including consumers, insurance companies and other third-party payers for overcharges paid for Cardizem CD between 1998 and 2003.

Read More →

Maryland et al v. Mitsubishi Electronics America; 1992-1 Trade Cas. (CCH) ¶69,743 (D. Md. 1992)

October 9, 2020

Plaintiff States sought damages and injunctive relief, alleging that Mitsubishi Electronics America, Inc. (MELA) conspired with its dealers to set or maintain the resale price of its electronics equipment. In the settlement with Plaintiff States, MELA was enjoined from engaging in the alleged conduct and agreed to pay $6 million dollars for administrative costs and to reimburse qualified buyers.

Read More →

New York et al. v. Hoffmann-LaRoche, Inc., Roche Vitamin, Inc.; Aventis Animal Nutrition S.A.; Daiichi Pharmaceutical Co. LTD; Eisai Co, LTD; Takeda Chemical Industries, Ltd; BASF Corporation (master case)

October 9, 2020

In various state court filings around the country, Plaintiff States alleged that Defendants conspired to set the prices of vitamins that go into various products. The exemplar case upon which all other settlements were ultimately based was filed in the District of Columbia in conjunction with various private class actions.

Read More →

New York et al. v. Matsushita Electric Corp. of America (S.D.N.Y. 1989)

October 9, 2020

Plaintiff States sued for damages and injunctive relief on their own behalf and as parens patriae. The complaint alleged that Defendant conspired to fix or maintain the resale price for which dealers were able to sell Matsushita?s products. The case was settled. Plaintiff States were awarded damages and injunctive relief.

Read More →

Missouri v. American Cyanamid Co.; 1997 U.S. Dist. LEXIS 4722,.1997-1 Trade Cas. (CCH) 71,712 (W.D. MO. 1997)

October 9, 2020

The Plaintiff States alleged that between 1989 and 1995, American Cyanamid Company (American Cyanamid) entered into contracts for Crop Protection Chemicals (CPC), with its dealers in which they agreed formally and in writing to a rebate program that held floor prices at levels equal to Defendant’s wholesale prices for affected CPC.

Read More →

Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.)

October 9, 2020

Plaintiff States sought damages and injunctive relief, alleging that the drug company, Bristol-Myers Squibb, Co. (BMS) wrongfully maintained a monopoly on Taxol, a drug for which the Plaintiff States alleged Defendant fraudulently filed a patent. BMS’s alleged wrongful action delayed entry into the market by generic competitors of the drug, resulting in higher prices for Taxol. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlemen, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →

Florida, et al. v. Nine West Group, Inc. and John Doe, 1-500, 80 F. Supp.2d 181 (S.D.N.Y. 2000); No. 00-CV-1707 (S.D.N.Y. Dec. 14, 2000)

October 9, 2020

Plaintiff States sought damages and injunctive relief, alleging that Nine West Group (Nine West) conspired with unnamed dealers to set the minimum resale price at
which retailers were permitted to sell women’s dress shoes to customers.

Read More →

Attorneys General Call for New Consumer Protections to Protect Airline Industry Customers

October 8, 2020

State attorneys general are on the front lines of protecting American consumers from deceptive and unfair practices by industries. To that end, we strongly urge Congress that any further financial relief provided to the airline industry be coupled with, or followed by, appropriate consumer protection measures.

Read More →

NAAG Endorses First Step Act

October 7, 2020

As our jurisdictions’ Attorneys General, public safety and the faithful execution of the law fall squarely on our shoulder. Constituents hold us uniquely accountable for ensuring our communities provide a safe place to work and raise a family. To that end, we have supported legislation that strongly punishes criminal conduct while making sure people exiting prison pose less of a threat than when they entered.

Read More →

AGs Urge Health Insurance Companies to Reduce Provider Incentives for Prescribing Pain Killers

October 7, 2020

The undersigned State Attorneys General are urging America’s Health Insurance Plans (AHIP) to take proactive steps to encourage your members to review their payment and coverage policies and revise them, as necessary and appropriate, to encourage healthcare providers to prioritize non-opioid pain management options over opioid prescriptions for the treatment of chronic, non-cancer pain.

Read More →